Bristol and AstraZeneca lost major PPAR diabetes product development projects. Both companies got a nasty taste of a rapidly emerging force in the drug development process: the academic research organization. These academic centers are not shy about expressing their negative as well as positive opinions on drug development plans. Leading the pack is the Cleveland Clinic - the source of the safety questions that finished off the PPAR class.
Cole Werble
The pen is mightier than an FDA review—or at least it probably feels that way to PPAR drug developers.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
FDA Commissioner Martin Makary will give industry a new avenue for access and influence despite his and HHS Secretary Robert F. Kennedy Jr.’s claims that the pharma-FDA relationship is too cozy.
Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.
Pink Sheet reporter and editors discuss the new clinical trial requirements that the FDA announced for COVID-19 vaccines, the updated label for Novavax’s newly approved COVID-19 vaccine, and other vaccine-related events that were part of a busy week for policy in the sector.
The FDA’s advisors split on whether to update COVID-19 vaccines for the fall. The agency refused to discuss the impact of the new vaccine framework on availability.
Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.
Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.
The verdict by the Unified Patent Court in the dispute between Sanofi/Regeneron Pharmaceuticals and Amgen explains what companies should look out for when deciding whether infringement has taken place when it comes to second medical use patents.
